| Literature DB >> 33795235 |
Matthew Z Madden1, Jeffrey C Rathmell2.
Abstract
Immune oncology approaches of adoptive cell therapy and immune checkpoint blockade aim to activate T cells to eliminate tumors. Normal stimulation of resting T cells induces metabolic reprogramming from catabolic and oxidative metabolism to aerobic glycolysis in effector T cells, and back to oxidative metabolism in long-lived memory cells. These metabolic reprogramming events are now appreciated to be essential aspects of T-cell function and fate. Here, we review these transitions, how they are disrupted by T-cell interactions with tumors and the tumor microenvironment, and how they can inform immune oncology to enhance T-cell function against tumors. SIGNIFICANCE: T-cell metabolism plays a central role in T-cell fate yet is altered in cancer in ways that can suppress antitumor immunity. Here, we discuss challenges and opportunities to stimulate effector T-cell metabolism and improve cancer immunotherapy. ©2021 American Association for Cancer Research.Entities:
Mesh:
Year: 2021 PMID: 33795235 PMCID: PMC8295173 DOI: 10.1158/2159-8290.CD-20-0569
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397